Recruitment Status

Recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

22012

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: JNJ-90301900, Durvalumab, Concurrent Chemo/Radiation Therapy (cCRT), Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin, Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel; Drug · Biological · Radiation
Lead sponsor: Johnson & Johnson Enterprise Innovation Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 18
States / cities: La Jolla, California • Farmington, Connecticut • New Haven, Connecticut + 14 more

Conditions: Depressive Disorder, Major
Interventions: Seltorexant, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 39
States / cities: Bryant, Arkansas • Bellflower, California • Glendale, California + 31 more

Conditions: Mantle Cell Lymphoma
Interventions: Zanubrutinib, Rituximab, Patient Observation, Bone Marrow Biopsy, Fludeoxyglucose F-18, Positron Emission Tomography, Computed Tomography, Magnetic Resonance Imaging, Esophagogastroduodenoscopy, Colonoscopy, Biospecimen Collection, Questionnaire Administration; Drug · Biological · Other + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 60 Years and older
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2038
U.S. locations: 242
States / cities: Little Rock, Arkansas • Beverly Hills, California • Duarte, California + 189 more

Conditions: Metastatic Soft-tissue Sarcoma
Interventions: Cyclophosphamide, T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Castration-resistant Prostatic Neoplasms
Interventions: Pasritamig, Placebo, Best Supportive Care (BSC), JNJ-87189401; Biological · Other · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 55
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 43 more

Conditions: Severe Combined Immunodeficiency
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 6 Months to 99 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Disruptive Behavior Disorders, Conduct Disorder, Oppositional Defiant Disorder, Attention-deficit/Hyperactivity Disorder
Interventions: Psychotherapy; Behavioral
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 8 Years to 13 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2037
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Interventions: Pelabresib, Ruxolitinib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 22
States / cities: Denver, Colorado • New Haven, Connecticut • Fort Myers, Florida + 19 more

Conditions: Alzheimer Disease
Interventions: Donanemab, Usual Care; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 60 Years and older
Enrollment: 6,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: Huntsville, Alabama

Conditions: Hemolytic Disease of the Fetus and Newborn
Interventions: Standard of Care; Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 5
States / cities: Indianapolis, Indiana • Rochester, New York • Cincinnati, Ohio + 2 more

Conditions: Severe Aplastic Anemia, Telomere Biology Disorders, Inherited Bone Marrow Failure Syndromes
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 99 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2041
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Herpes Zoster
Interventions: Shingrix; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Recruiting clinical trials

Filter and sort this status page

Live official records

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

Genetic Basis of Immunodeficiency

Augmenting Parent Management Training for Child Temper Outbursts Using a Digital Tool

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease

A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry

Natural History of Acquired and Inherited Bone Marrow Failure Syndromes

Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population